



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on December 24, 2003.

SUPPLEMENTAL AMENDMENT UNDER
37 CFR §1.111
Examining Group 1631
Patent Application
Docket No. G-142US05REG
Serial No. 09/978,418

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Carolyn L. Smith
Art Unit : 1631
Applicants : Stephane Bejanin, Hiroaki Tanaka
Serial No. : 09/978,418
Filed : October 15, 2001
Conf. No. : 7350
For : Cytogram Polypeptides and Uses Thereof

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL AMENDMENT UNDER 37 CFR §1.111

Sir:

In a Communication dated November 25, 2003, the Office Action indicates that Applicants' Amendment filed on September 15, 2003 in the above-referenced patent application is non-responsive to the previous Office Action. Specifically, the Office Action indicates that the application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because it lacks SEQ ID NOs. cited along with each sequence in the specification.

By this Supplemental Amendment, Applicants have amended the subject specification to include a SEQ ID NO. for the sequences not previously identified throughout the application. In addition, a Submission of Sequence Listing Under §1.821, including a replacement sequence listing on paper and a computer readable format, is attached. Accordingly, reconsideration and withdrawal of the objection is respectfully requested.

Applicants are resubmitting with this Supplemental Amendment their remarks previously submitted to the Patent Office on September 15, 2003 in response to the Office Action dated April 14, 2003. Accordingly, please amend the subject application as follows: